Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.61 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.61 |
| ▸ | FNTA | P49354 | 15/20 | 0.53 |
| ▸ | FNTB | P49356 | 15/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133785 | 0.88 | PLA2G1B (0.78) | PLA2G1BATG4BFNTAFNTBGRIA2 | |
| SCHEMBL3137792 | 0.84 | PLA2G1B (0.61) | PLA2G1BATG4BFNTAFNTBGRIA2 | |
| SCHEMBL3129020 | 0.84 | FNTA (0.55) | FNTAFNTBGRIA2GRIA4KDM4E | |
| SCHEMBL3128242 | 0.84 | L3MBTL1 (0.56) | FNTAFNTBKDM4EALDH1A1HPGD | |
| SCHEMBL3135084 | 0.83 | FNTA (0.63) | FNTAFNTBGRIA2GRIA4KDM4E | |
| SCHEMBL3139516 | 0.83 | L3MBTL1 (0.49) | PLA2G1BATG4BFNTAFNTBGRIA2 | |
| SCHEMBL3138034 | 0.82 | FNTA (0.59) | FNTAFNTBKDM4EALDH1A1HPGD | |
| SCHEMBL8280703 | 0.82 | FNTA (0.53) | FNTAFNTBKDM4EALDH1A1HPGD | |
| SCHEMBL3128690 | 0.81 | GRIA2 (0.54) | FNTAFNTBGRIA2GRIA4KDM4E | |
| SCHEMBL13522749 | 0.78 | FNTA (0.81) | FNTAFNTBKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | PLA2G1B 3668/4885ATG4B 1274/4885FNTA 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.